141 related articles for article (PubMed ID: 31814132)
1. Search for Natural Compounds That Increase Apolipoprotein A-I Transcription in HepG2 Cells: Specific Attention for BRD4 Inhibitors.
van der Krieken SE; van-der Pijl PC; Lin Y; Popeijus HE; Mensink RP; Plat J
Lipids; 2019 Nov; 54(11-12):687-695. PubMed ID: 31814132
[TBL] [Abstract][Full Text] [Related]
2. Large-Scale Screening of Natural Products Transactivating Peroxisome Proliferator-Activated Receptor α Identifies 9S-Hydroxy-10E,12Z,15Z-Octadecatrienoic Acid and Cymarin as Potential Compounds Capable of Increasing Apolipoprotein A-I Transcription in Human Liver Cells.
van der Krieken SE; Popeijus HE; Bendik I; Böhlendorf B; Konings MCJM; Tayyeb J; Mensink RP; Plat J
Lipids; 2018 Nov; 53(11-12):1021-1030. PubMed ID: 30706477
[TBL] [Abstract][Full Text] [Related]
3. Short-Chain Fatty Acids (Except Hexanoic Acid) Lower NF-kB Transactivation, Which Rescues Inflammation-Induced Decreased Apolipoprotein A-I Transcription in HepG2 Cells.
Tayyeb JZ; Popeijus HE; Mensink RP; Konings MCJM; Mokhtar FBA; Plat J
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708494
[TBL] [Abstract][Full Text] [Related]
4. Link Between ER-Stress, PPAR-Alpha Activation, and BET Inhibition in Relation to Apolipoprotein A-I Transcription in HepG2 Cells.
van der Krieken SE; Popeijus HE; Mensink RP; Plat J
J Cell Biochem; 2017 Aug; 118(8):2161-2167. PubMed ID: 28012209
[TBL] [Abstract][Full Text] [Related]
5. Amoxicillin Modulates ApoA-I Transcription and Secretion, Predominantly via PPARα Transactivation Inhibition.
Tayyeb JZ; Popeijus HE; Mensink RP; Konings MCJM; Mulders KHR; Plat J
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31783518
[TBL] [Abstract][Full Text] [Related]
6. A novel compound 4010B-30 upregulates apolipoprotein A-I gene expression through activation of PPARγ in HepG2 cells.
Du Y; Wang L; Si S; Yang Y; Hong B
Atherosclerosis; 2015 Apr; 239(2):589-98. PubMed ID: 25734982
[TBL] [Abstract][Full Text] [Related]
7. Bromodomain-Containing Protein 4: A Druggable Target.
Shi Y; Liu J; Zhao Y; Cao J; Li Y; Guo F
Curr Drug Targets; 2019; 20(15):1517-1536. PubMed ID: 31215391
[TBL] [Abstract][Full Text] [Related]
8. Butyric Acid Added Apically to Intestinal Caco-2 Cells Elevates Hepatic ApoA-I Transcription and Rescues Lower ApoA-I Expression in Inflamed HepG2 Cells Co-Cultured in the Basolateral Compartment.
Tayyeb JZ; Popeijus HE; Mensink RP; Plat J
Biomolecules; 2021 Jan; 11(1):. PubMed ID: 33430253
[TBL] [Abstract][Full Text] [Related]
9. Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor.
Hu J; Wang Y; Li Y; Xu L; Cao D; Song S; Damaneh MS; Wang X; Meng T; Chen YL; Shen J; Miao Z; Xiong B
Eur J Med Chem; 2017 Sep; 137():176-195. PubMed ID: 28586718
[TBL] [Abstract][Full Text] [Related]
10. Synthesis of recombinant high density lipoprotein with apolipoprotein A-I and apolipoprotein A-V.
Zhang X; Chen B
Biol Chem; 2011 May; 392(5):423-9. PubMed ID: 21476871
[TBL] [Abstract][Full Text] [Related]
11. 3-Hydroxyisoindolin-1-one derivates: Synthesis by palladium-catalyzed CH activation as BRD4 inhibitors against human acute myeloid leukemia (AML) cells.
Chen P; Yang Y; Yang L; Tian J; Zhang F; Zhou J; Zhang H
Bioorg Chem; 2019 May; 86():119-125. PubMed ID: 30690335
[TBL] [Abstract][Full Text] [Related]
12. PPARγ Represses Apolipoprotein A-I Gene but Impedes TNFα-Mediated ApoA-I Downregulation in HepG2 Cells.
Shavva VS; Mogilenko DA; Bogomolova AM; Nikitin AA; Dizhe EB; Efremov AM; Oleinikova GN; Perevozchikov AP; Orlov SV
J Cell Biochem; 2016 Sep; 117(9):2010-22. PubMed ID: 26813964
[TBL] [Abstract][Full Text] [Related]
13. RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist.
McLure KG; Gesner EM; Tsujikawa L; Kharenko OA; Attwell S; Campeau E; Wasiak S; Stein A; White A; Fontano E; Suto RK; Wong NC; Wagner GS; Hansen HC; Young PR
PLoS One; 2013; 8(12):e83190. PubMed ID: 24391744
[TBL] [Abstract][Full Text] [Related]
14. The therapeutic potential of BRD4 in cardiovascular disease.
Lin S; Du L
Hypertens Res; 2020 Oct; 43(10):1006-1014. PubMed ID: 32409773
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological evaluation of novel 4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridine derivatives as potential BRD4 inhibitors.
Bi X; Li J; Li J; Shi W; Dai Y; Li Q; Zhang W; Huang W; Qian H; Jiang C
Bioorg Med Chem; 2019 Jul; 27(13):2813-2821. PubMed ID: 31079968
[TBL] [Abstract][Full Text] [Related]
16. A natural compound, aristoyagonine, is identified as a potent bromodomain inhibitor by mid-throughput screening.
Kim YH; Kim M; Yoo M; Kim JE; Lee HK; Heo JN; Lee CO; Yoo M; Jung KY; Yun CS; Moon SW; Chang HK; Chung CW; Pyo S; Choi SU; Park CH
Biochem Biophys Res Commun; 2018 Sep; 503(2):882-887. PubMed ID: 29928885
[TBL] [Abstract][Full Text] [Related]
17. Effect of chromium on apolipoprotein A-I expression in HepG2 cells.
Haas MJ; Sawaf R; Horani MH; Gobal F; Wong NC; Mooradian AD
Nutrition; 2003 Apr; 19(4):353-7. PubMed ID: 12679171
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological evaluation of 3,5-dimethylisoxazole and pyridone derivatives as BRD4 inhibitors.
Rong J; Feng ZZ; Shi YJ; Ren J; Xu Y; Wang NY; Xue Q; Liu KL; Zhou SY; Wei W; Yu LT
Bioorg Med Chem Lett; 2019 Oct; 29(19):126577. PubMed ID: 31421967
[TBL] [Abstract][Full Text] [Related]
19. A patent review of BRD4 inhibitors (2013-2019).
Lu T; Lu W; Luo C
Expert Opin Ther Pat; 2020 Jan; 30(1):57-81. PubMed ID: 31815566
[No Abstract] [Full Text] [Related]
20. Computational study on the selective inhibition mechanism of MS402 to the first and second bromodomains of BRD4.
Wang Q; Li Y; Xu J; Wang Y; Shi D; Liu L; Leung EL; Yao X
Proteins; 2019 Jan; 87(1):3-11. PubMed ID: 30260047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
